Celgene beats estimates as earnings leap more than 30%

1 November 2019

Third-quarter 2019 sales for US biotech Celgene (Nasdaq: CELG) came in at $4.52 billion, up 16% year-on-year and beating consensus forecasts of $4.41 billion, said the company, which is soon to become part of Bristol-Myers Squibb (NYSE: BMY) in a $74 billion acquisition announced earlier this year.

Adjusted net income for the third quarter of 2019 increased 33% to $2.18 billion. For the same period, adjusted diluted earnings per share (EPS) increased 31% to $2.99 from $2.29, ahead of the $2.70 FactSet consensus. Celgene’s shares dipped 0.18% to $107.84 in after-hours trading, when the results were released.

“Across functions and around the world, our teams delivered outstanding third quarter results,” said Mark Alles, chairman and chief executive of Celgene, adding: “We are continuing to advance multiple high-potential medicines toward regulatory approvals and look forward to closing the Bristol-Myers Squibb transaction by the end of the year.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK